AlphaCrest Capital Management’s Blueprint Medicines BPMC Stock Holding History

AlphaCrest Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,236	Closed	-$411K	–	165
2022 Q3	$411K	Buy	6,236 +1,353	+28%	+$86.9K	0.03%	1051
2022 Q2	$247K	Sell	4,883 -2,584	-35%	-$151K	0.01%	1163
2022 Q1	$477K	Buy	+7,467	New	+$536K	0.03%	918
2021 Q3	–	Sell	-2,864	Closed	-$252K	–	1251
2021 Q2	$252K	Sell	2,864 -15,432	-84%	-$1.41M	0.01%	1151
2021 Q1	$1.78M	Buy	18,296 +9,486	+108%	+$947K	0.1%	293
2020 Q4	$988K	Buy	+8,810	New	+$928K	0.08%	323
2020 Q2	–	Sell	-9,300	Closed	-$544K	–	916
2020 Q1	$544K	Buy	+9,300	New	+$598K	0.07%	529

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AlphaCrest Capital Management's BPMC Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 6,236 shares — an estimated $411K sold.

AlphaCrest Capital Management first reported a position in BPMC in Q1 2020 and held it in 7 quarters. The position peaked at $1.78M in Q1 2021. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

AlphaCrest Capital Management reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 6,236 Blueprint Medicines shares in Q4 2022, an estimated $411K.
AlphaCrest Capital Management first reported a position in Blueprint Medicines in Q1 2020 and held it in 7 quarters.
AlphaCrest Capital Management's Blueprint Medicines position peaked at $1.78M in Q1 2021.
223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.